J 2012

Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin - Frankfurt-Münster (BFM) protokols

LEJHANCOVÁ-TOUŠOVSKÁ, Kateřina, Ondřej ZAPLETAL, Soňa VYTISKOVÁ, Petra STRBÁČKOVÁ, Jaroslav ŠTĚRBA et. al.

Základní údaje

Originální název

Profile of thrombin generation in children with acute lymphoblastic leukemia treated by Berlin - Frankfurt-Münster (BFM) protokols

Autoři

LEJHANCOVÁ-TOUŠOVSKÁ, Kateřina, Ondřej ZAPLETAL, Soňa VYTISKOVÁ, Petra STRBÁČKOVÁ a Jaroslav ŠTĚRBA

Vydání

Blood Coagulation and Fibrinolysis, 2012, 0957-5235

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.248

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000300124900006

Klíčová slova anglicky

acute lymphoblastic leukemia; chemotherapy; pediatric hematology/oncology; thrombin generation; thrombosis

Příznaky

Mezinárodní význam
Změněno: 1. 11. 2016 08:23, RNDr. Soňa Vytisková, Ph.D.

Anotace

V originále

Treatment with L-asparaginase is associated with coagulation disturbances with deep venous thrombosis being the most common clinical consequence. Use of the calibrated automated thrombogram allows precise estimation of thrombin generated in vitro. We show the first data on thrombin generation, measured by calibrated automated thrombography (CAT), in children with acute lymphoblastic leukemia treated with L-asparaginase. Thrombin generation was measured by means of CAT in 23 children treated for acute lymphoblastic leukemia. Samples were obtained at predefined time points during the induction and reinduction phase of acute lymphoblastic leukemia-intercontinental Berlin-Frankfurt-Munster (BFM) 2000 or Associazione Italiana Ematologica Oncologia Pedaitrica Interim BFM 2000 protocols. Antihrombin and fibrinogen were measured on the same sample. Twenty-eight sets of thrombin generation measurements were collected from 23 patients. We observed no significant effect of antithrombin deficiency and/or hypofibrinogenemia on thrombin generation. Endogenous thrombin generation and peak thrombin were significantly higher during induction than in the reinduction phase (P<0.001). Four patients with severe infection experienced an increase in thrombin generation, reaching maximum in a median of 7.5 days after the onset of infection. Two of those patients developed deep venous thrombosis at the time of peaked endogenous thrombin generation. Thrombin generation in children with acute lymphoblastic leukemia treated according to BFM protocols is significantly higher during the induction phase compared with reinduction and is not substantially affected by hypofibrinogenemia and/or antithrombin deficiency. Severe infection during the induction phase enhances thrombin generation with subsequent risk of thrombosis.